Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSRI/Clomipramine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| quetiapine fumarate | DRUG | - |
| SSRI/Clomipramine | DRUG | - |
Inclusion Criteria: * Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine Exclusion Criteria: * Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intole...
SSRI/Clomipramine is a small molecule being studied for use in Major Depressive Disorder and Obsessive Compulsive Disorder. It is an investigational therapy in Phase 3 clinical development for these psychiatric conditions. The drug is being developed by AstraZeneca PLC.
SSRI/Clomipramine is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the drug for psychiatric indications including Major Depressive Disorder and Obsessive Compulsive Disorder.
SSRI/Clomipramine is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 3 trials for this drug have been completed, with studies conducted in multiple countries across Europe and Australia.
SSRI/Clomipramine has been studied in two completed Phase 3 clinical trials. One trial, NCT00254735, evaluated the drug in patients with Obsessive Compulsive Disorder in Germany. Another trial, NCT00789854, compared the drug in patients with Major Depressive Disorder and Treatment Resistant Depression across multiple countries.
SSRI/Clomipramine is being studied in clinical trials that also involve quetiapine. The trial NCT00254735 examined quetiapine augmentation in Obsessive Compulsive Disorder, and NCT00789854 compared quetiapine XR with lithium augmentation in treatment resistant depression. SSRI/Clomipramine itself is a separate drug being evaluated in these studies.